Ascendis Pharma A/S
ASND
View Detailed Chart
213.240USD
-7.180-3.26%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
13.16BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.26%
5 Days
+2.95%
1 Month
+4.32%
6 Months
+24.85%
Year to Date
+54.89%
1 Year
+64.19%
View Detailed Chart
TradingKey Stock Score of Ascendis Pharma A/S
Currency: USD Updated: 2025-12-12Key Insights
Ascendis Pharma A/S's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 2/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 261.07.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ascendis Pharma A/S's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
17
analysts
Strong Buy
Current Rating
261.066
Target Price
+26.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Ascendis Pharma A/S Highlights
StrengthsRisks
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 719.04% year-on-year.
Undervalued
The company’s latest PE is -21.72, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 68.62M shares, increasing 0.00% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 682.00 shares of this stock.
Ascendis Pharma A/S News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ascendis Pharma A/S Info
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Ticker SymbolASND
CompanyAscendis Pharma A/S
CEOMoller Mikkelsen (Jan)
Websitehttps://ascendispharma.dk/
FAQs
What is the current price of Ascendis Pharma A/S (ASND)?
The current price of Ascendis Pharma A/S (ASND) is 213.240.
What is the symbol of Ascendis Pharma A/S?
The ticker symbol of Ascendis Pharma A/S is ASND.
What is the 52-week high of Ascendis Pharma A/S?
The 52-week high of Ascendis Pharma A/S is 229.940.
What is the 52-week low of Ascendis Pharma A/S?
The 52-week low of Ascendis Pharma A/S is 118.030.
What is the market capitalization of Ascendis Pharma A/S?
The market capitalization of Ascendis Pharma A/S is 13.16B.
What is the net income of Ascendis Pharma A/S?
The net income of Ascendis Pharma A/S is -378.08M.
Is Ascendis Pharma A/S (ASND) currently rated as Buy, Hold, or Sell?
According to analysts, Ascendis Pharma A/S (ASND) has an overall rating of --, with a price target of 261.066.
What is the Earnings Per Share (EPS TTM) of Ascendis Pharma A/S (ASND)?
The Earnings Per Share (EPS TTM) of Ascendis Pharma A/S (ASND) is -10.147.
Related Instruments
+3.38%
+1.22%
+1.85%
+1.93%
+1.98%
-0.04%
+2.38%
+0.38%
+2.24%
-0.51%
-1.77%
+0.81%
+3.59%
+1.13%
+0.88%
+3.26%
+1.53%
0.00%
+1.96%
-3.07%
